Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target

Ramy F. Youssef, Payal Kapur, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim, Yair Lotan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: We evaluated the association of fibroblast growth factor (FGF2) expression with pathologic features and clinical outcomes of squamous cell carcinoma (SCC) of the urinary bladder.

METHODS: Immunohistochemistry of FGF2 was performed on radical cystectomy specimens with pure SCC from 1997 to 2003. The relationship between FGF2 and pathologic parameters and oncological outcome was assessed.

RESULTS: The study included 151 patients with SCC (98 men) with a median age of 52 years (range: 36-74 y). Schistosomal infection was found in 81% of patients. Pathologic category was T2 and T3 in 88% of patients and the grade was low in>50%. Lymph node invasion and lymphovascular invasion were found in 30.5% and 16%. Altered FGF2 was associated with tumor grade (P = 0.014), lymph node invasion, and lymphovascular invasion (P = 0.042). Altered FGF2 was associated with both disease recurrence and cancer-specific mortality (P≤0.001) in Kaplan-Meier analyses and was an independent predictor of cancer recurrence (hazard ratio = 2.561, P = 0. 009) and cancer-specific mortality (hazard ratio = 2.679, P = 0. 033) in multivariate Cox regression analyses. Adding FGF2 to a model including standard clinicopathologic prognostics (pathologic T category, lymph node status, and grade) showed a significant improvement (6%) in accuracy of prediction poor oncological outcome.

CONCLUSIONS: FGF2 overexpression is associated with aggressive pathologic features and worse outcomes after radical cystectomy for SCC, suggesting a good prognostic and possible therapeutic role.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Fibroblast Growth Factors
Fibroblast Growth Factor 2
Squamous Cell Carcinoma
Urinary Bladder
Biomarkers
Cystectomy
Lymph Nodes
Therapeutics
Neoplasms
Recurrence
Mortality
Kaplan-Meier Estimate
Immunohistochemistry
Regression Analysis
Infection

Keywords

  • Biomarkers
  • Bladder cancer
  • FGF2
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Role of fibroblast growth factor in squamous cell carcinoma of the bladder : prognostic biomarker and potential therapeutic target. / Youssef, Ramy F.; Kapur, Payal; Mosbah, Ahmed; Abol-Enein, Hassan; Ghoneim, Mohamed; Lotan, Yair.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 33, No. 3, 01.03.2015.

Research output: Contribution to journalArticle

@article{21e2e7f8654243dda3cb6ed733efc25f,
title = "Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target",
abstract = "BACKGROUND: We evaluated the association of fibroblast growth factor (FGF2) expression with pathologic features and clinical outcomes of squamous cell carcinoma (SCC) of the urinary bladder.METHODS: Immunohistochemistry of FGF2 was performed on radical cystectomy specimens with pure SCC from 1997 to 2003. The relationship between FGF2 and pathologic parameters and oncological outcome was assessed.RESULTS: The study included 151 patients with SCC (98 men) with a median age of 52 years (range: 36-74 y). Schistosomal infection was found in 81{\%} of patients. Pathologic category was T2 and T3 in 88{\%} of patients and the grade was low in>50{\%}. Lymph node invasion and lymphovascular invasion were found in 30.5{\%} and 16{\%}. Altered FGF2 was associated with tumor grade (P = 0.014), lymph node invasion, and lymphovascular invasion (P = 0.042). Altered FGF2 was associated with both disease recurrence and cancer-specific mortality (P≤0.001) in Kaplan-Meier analyses and was an independent predictor of cancer recurrence (hazard ratio = 2.561, P = 0. 009) and cancer-specific mortality (hazard ratio = 2.679, P = 0. 033) in multivariate Cox regression analyses. Adding FGF2 to a model including standard clinicopathologic prognostics (pathologic T category, lymph node status, and grade) showed a significant improvement (6{\%}) in accuracy of prediction poor oncological outcome.CONCLUSIONS: FGF2 overexpression is associated with aggressive pathologic features and worse outcomes after radical cystectomy for SCC, suggesting a good prognostic and possible therapeutic role.",
keywords = "Biomarkers, Bladder cancer, FGF2, Squamous cell carcinoma",
author = "Youssef, {Ramy F.} and Payal Kapur and Ahmed Mosbah and Hassan Abol-Enein and Mohamed Ghoneim and Yair Lotan",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.urolonc.2014.09.020",
language = "English (US)",
volume = "33",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Role of fibroblast growth factor in squamous cell carcinoma of the bladder

T2 - prognostic biomarker and potential therapeutic target

AU - Youssef, Ramy F.

AU - Kapur, Payal

AU - Mosbah, Ahmed

AU - Abol-Enein, Hassan

AU - Ghoneim, Mohamed

AU - Lotan, Yair

PY - 2015/3/1

Y1 - 2015/3/1

N2 - BACKGROUND: We evaluated the association of fibroblast growth factor (FGF2) expression with pathologic features and clinical outcomes of squamous cell carcinoma (SCC) of the urinary bladder.METHODS: Immunohistochemistry of FGF2 was performed on radical cystectomy specimens with pure SCC from 1997 to 2003. The relationship between FGF2 and pathologic parameters and oncological outcome was assessed.RESULTS: The study included 151 patients with SCC (98 men) with a median age of 52 years (range: 36-74 y). Schistosomal infection was found in 81% of patients. Pathologic category was T2 and T3 in 88% of patients and the grade was low in>50%. Lymph node invasion and lymphovascular invasion were found in 30.5% and 16%. Altered FGF2 was associated with tumor grade (P = 0.014), lymph node invasion, and lymphovascular invasion (P = 0.042). Altered FGF2 was associated with both disease recurrence and cancer-specific mortality (P≤0.001) in Kaplan-Meier analyses and was an independent predictor of cancer recurrence (hazard ratio = 2.561, P = 0. 009) and cancer-specific mortality (hazard ratio = 2.679, P = 0. 033) in multivariate Cox regression analyses. Adding FGF2 to a model including standard clinicopathologic prognostics (pathologic T category, lymph node status, and grade) showed a significant improvement (6%) in accuracy of prediction poor oncological outcome.CONCLUSIONS: FGF2 overexpression is associated with aggressive pathologic features and worse outcomes after radical cystectomy for SCC, suggesting a good prognostic and possible therapeutic role.

AB - BACKGROUND: We evaluated the association of fibroblast growth factor (FGF2) expression with pathologic features and clinical outcomes of squamous cell carcinoma (SCC) of the urinary bladder.METHODS: Immunohistochemistry of FGF2 was performed on radical cystectomy specimens with pure SCC from 1997 to 2003. The relationship between FGF2 and pathologic parameters and oncological outcome was assessed.RESULTS: The study included 151 patients with SCC (98 men) with a median age of 52 years (range: 36-74 y). Schistosomal infection was found in 81% of patients. Pathologic category was T2 and T3 in 88% of patients and the grade was low in>50%. Lymph node invasion and lymphovascular invasion were found in 30.5% and 16%. Altered FGF2 was associated with tumor grade (P = 0.014), lymph node invasion, and lymphovascular invasion (P = 0.042). Altered FGF2 was associated with both disease recurrence and cancer-specific mortality (P≤0.001) in Kaplan-Meier analyses and was an independent predictor of cancer recurrence (hazard ratio = 2.561, P = 0. 009) and cancer-specific mortality (hazard ratio = 2.679, P = 0. 033) in multivariate Cox regression analyses. Adding FGF2 to a model including standard clinicopathologic prognostics (pathologic T category, lymph node status, and grade) showed a significant improvement (6%) in accuracy of prediction poor oncological outcome.CONCLUSIONS: FGF2 overexpression is associated with aggressive pathologic features and worse outcomes after radical cystectomy for SCC, suggesting a good prognostic and possible therapeutic role.

KW - Biomarkers

KW - Bladder cancer

KW - FGF2

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85003052715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003052715&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.09.020

DO - 10.1016/j.urolonc.2014.09.020

M3 - Article

C2 - 25477183

AN - SCOPUS:84925300588

VL - 33

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 3

ER -